Related Experiment Video
Updated: Jun 24, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Dendritic pathology in Alzheimer's disease
1Department of Neurology, Aristotelian University, Thessaloniki 540 06, Greece. sibh844@otenet.gr
Journal of the Neurological Sciences
|March 20, 2009
Summary
Mitochondrial damage in Alzheimer's disease (AD) is linked to dendritic degeneration and spine loss. Protecting mitochondria may offer a therapeutic strategy for AD.
Area of Science:
- Neuroscience
- Pathology
- Cell Biology
Background:
- Dendritic pathology and reduced dendritic spine density are hallmarks of early Alzheimer's disease (AD), correlating with cognitive decline.
- Previous research identified pathological alterations in dendrites and dendritic spines in the prefrontal cortex and cerebellum in AD.
Purpose of the Study:
- To describe and quantify morphological alterations of dendrites and dendritic spines in the acoustic and visual cortices of Alzheimer's disease patients.
- To investigate ultrastructural changes in mitochondria within dendritic profiles and spines and their correlation with dendritic pathology.
Main Methods:
- Golgi staining and electron microscopy were applied to analyze brain tissue from eleven Alzheimer's disease cases.
- Morphological and ultrastructural analyses focused on dendrites, dendritic spines, and mitochondria within these structures.
Main Results:
- Significant morphological alterations in dendrites and dendritic spines were observed in the acoustic and visual cortices.
- Mitochondrial pathology within dendritic profiles and spines showed a substantial correlation with dystrophic dendrites, loss of dendritic branches, and altered dendritic spines.
Conclusions:
- Mitochondrial alterations are hypothesized to play a critical role in dendritic degeneration and the loss of dendritic spines in Alzheimer's disease.
- Therapeutic strategies aimed at protecting mitochondria may hold potential benefits for treating Alzheimer's disease.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...